Aprea Therapeutics (APRE) Q3 2026 earnings summary

Executive summary

• Q3 net loss widened to $4.81M from $2.97M YoY as R&D spending increased; cash and cash equivalents were $37.8M at Sept. 30, with operating runway projected into Q1 2028.

• APR-1051 remains the lead clinical program; ACESOT-1051 expanded to nine active sites, with early antitumor activity and manageable tolerability supporting biomarker-focused development.

Financial highlights

• Q3 2026 grant revenue was $0 versus $1,848 in Q3 2025; nine-month revenue was $0 versus $282,422 after NIH grants were exhausted.

• Q3 operating expenses rose 66% to $5.17M, including $3.34M R&D and $1.83M G&A, versus $3.12M total expenses a year earlier.

• Q3 net loss was $4.81M versus $2.97M YoY; nine-month net loss was $11.69M versus $10.14M.

• Nine-month operating expenses were $12.64M versus $10.87M; operating loss was $12.64M versus $10.59M.

Outlook and guidance

• ACESOT-1051 enrollment is expected to reach 6–10 patients monthly in Q4 2026; dose escalation and backfill enrollment are expected to complete in Q2 2027.

• Expansion aims to enroll at least 50 patients with uterine serous carcinoma or Cyclin E-overexpressing, platinum-resistant ovarian cancer; Part 2 dose selection is targeted for H1 2027.

• APR-1051 R&D expenses are expected to rise as the trial expands and additional sites activate; APR-1602/DYRK1A/B inhibitor lead identification is targeted for Q2 2027, subject to resources.

• Updated interim APR-1051 results are scheduled for oral presentation at ENA 2026 on November 20.